Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Lung Cell Mol Physiol ; 312(2): L217-L230, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-27881407

ABSTRACT

Sakuranetin is the main isolate flavonoid from Baccharis retusa (Asteraceae) leaves and exhibits anti-inflammatory and antioxidative activities. Acute respiratory distress syndrome is an acute failure of the respiratory system for which effective treatment is urgently necessary. This study investigated the preventive and therapeutic effects of sakuranetin on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. Animals were treated with intranasal sakuranetin 30 min before or 6 h after instillation of LPS. Twenty-four hours after ALI was induced, lung function, inflammation, macrophages population markers, collagen fiber deposition, the extent of oxidative stress, and the expression of matrix metalloprotease-9 (MMP-9), tissue inhibitor of MMP-9 (TIMP-1) and NF-κB were evaluated. The animals began to show lung alterations 6 h after LPS instillation, and these changes persisted until 24 h after LPS administration. Preventive and therapeutic treatment with sakuranetin reduced the neutrophils in the peripheral blood and in the bronchial alveolar lavage. Sakuranetin treatment also reduced macrophage populations, particularly that of M1-like macrophages. In addition, sakurnaetin treatment reduced keratinocyte-derived chemokines (IL-8 homolog) and NF-κB levels, collagen fiber formation, MMM-9 and TIMP-1-positive cells, and oxidative stress in lung tissues compared with LPS animals treated with vehicle. Finally, sakuranetin treatment also reduced total protein, and the levels of TNF-α and IL-1ß in the lung. This study shows that sakuranetin prevented and reduced pulmonary inflammation induced by LPS. Because sakuranetin modulates oxidative stress, the NF-κB pathway, and lung function, it may constitute a novel therapeutic candidate to prevent and treat ALI.


Subject(s)
Acute Lung Injury/drug therapy , Acute Lung Injury/prevention & control , Flavonoids/therapeutic use , Acute Lung Injury/blood , Acute Lung Injury/complications , Animals , Biomarkers/metabolism , Cell Polarity/drug effects , Collagen/metabolism , Compliance/drug effects , Cytokines/metabolism , Flavonoids/chemistry , Flavonoids/pharmacology , Inflammation Mediators/metabolism , Leukocytes/drug effects , Lipopolysaccharides , Lung/drug effects , Lung/metabolism , Lung/pathology , Male , Matrix Metalloproteinase 9/metabolism , Mice, Inbred BALB C , Models, Biological , Oxidative Stress/drug effects , Phosphorylation/drug effects , Pneumonia/blood , Pneumonia/complications , Pneumonia/drug therapy , Pneumonia/physiopathology , Protein Subunits/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Time Factors , Tissue Inhibitor of Metalloproteinase-1/metabolism , Transcription Factor RelA/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...